Article
Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.
Oncotarget - 23 Aug 2016
Ladd Brendon, Mazzola Anne Marie, Bihani Teeru, Lai Zhongwu, Bradford James, Collins Michael, Barry Evan, Goeppert Anne U, Weir Hazel M, Hearne Kelly, Renshaw Jonathan G, Mohseni Morvarid, Hurt Elaine, Jalla Sanjoo, Bao Haifeng, Hollingsworth Robert, Reimer Corinne, Zinda Michael, Fawell Stephen, D'Cruz Celina M
Abstract excerpt
Although endocrine therapy is successfully used to treat patients with estrogen receptor (ER) positive breast cancer, a substantial proportion of this population will relapse. Several mechanisms of acquired resistance have been described including activation of the mTOR pathway, increased activity of CDK4 and activating mutations in ER. Using a patient derived xenograft model harboring a common activating ER...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.